Anti trail r1 djr1

Manufactured by BioLegend

Anti-TRAIL-R1 (DJR1) is a monoclonal antibody that specifically binds to the TRAIL receptor 1 (TRAIL-R1), also known as DR4. TRAIL-R1 is a member of the tumor necrosis factor receptor superfamily and plays a role in apoptosis induction.

Automatically generated - may contain errors

Lab products found in correlation

Anti trail r2 djr2 4, by BioLegend (2 mentions) Mopc 21, by BioLegend (1 mentions) Anti granzyme b gb11, by BD (1 mentions)

Close spelling variants of this product

Anti-TRAIL (3 citations) TRAIL-R1 (2 citations)

2 protocols using anti trail r1 djr1

TRAIL Receptor Surface Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the TRAIL receptor stain we used monoclonal anti-TRAIL-R1 (DJR1) and anti-TRAIL-R2 (DJR2-4) antibodies (1 μg/10⁶ cells; BioLegend, San Diego, CA) that were conjugated to Phycoerythrin (PE). The isotype control antibody (MOPC-21) (1 μg/10⁶ cells) was also purchased from BioLegend. The surface expression of TRAIL receptors was measured by incubating cells with the PE-conjugated mouse anti-human TRAIL-R1 and mouse anti-human TRAIL-R2 antibodies as described previously [41 (link)].

Mohr A., Yu R, & Zwacka R.M. (2015). TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. BMC Cancer, 15, 494.

+ Open protocol

+ Expand

Immunophenotyping of NK Cells and Leukemic Blasts

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral whole blood (3 ml) was obtained at diagnosis for immunophenotyping by flow cytometry of NK cells and leukemic blasts. The following antibodies were used to enumerate NK cells and their surface expression: anti-KIR2DL1 (143211), anti-NTB-A (292811), anti-ULBP1 (170818), anti-ULBP2 (165903), anti-ULBP3 (166510), anti-MICA (159227), and anti-MICB (236511) were obtained from R&D Systems; anti-KIR3DL1 (DX9), anti-KIR2DL2/3 (CH-L), anti-CD11a (HI111), anti-NKG2D (1D11), anti-TRAIL (RIK-2), anti-DNAM (DX11), anti-2B4 (2–69), and anti-granzyme B (GB11) from BD Bioscience; anti-NKG2A (Z199), anti-NKp30 (Z25), anti-NKp44 (Z231), anti-NKp46 (BAB281), and anti-FAS (CIB2) from Beckman Coulter; and anti-FASL (14C2) from AbD Serotec. Blasts obtained at diagnosis were evaluated by anti-NTB-A (292811) from R&D Systems; anti-ICAM (84H10), anti-FAS (CIB2) and anti-CD48 (J4-57) from Beckman Coulter; anti-Nectin (R2.525) from BD Bioscience, anti-TRAIL-R1 (DJR1) and anti-TRAIL-R2 (DJR2-4) from Biolegend; anti-PVR (TX21) from MBL International; anti-HLA-ABCEFG (W6/32) from Dako; and anti-PI-9 (7D8) from AbD Serotec.

Sullivan E.M., Jeha S., Kang G., Cheng C., Rooney B., Holladay M., Bari R., Schell S., Tuggle M., Pui C.H, & Leung W. (2014). NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate to Post-induction Residual Disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(23), 5986-5994.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!